Amgen Inc. (NASDAQ:AMGN) Holdings Boosted by Godsey & Gibb Inc.

Godsey & Gibb Inc. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,003 shares of the medical research company's stock after acquiring an additional 1,285 shares during the quarter. Godsey & Gibb Inc.'s holdings in Amgen were worth $20,563,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. KFG Wealth Management LLC grew its stake in shares of Amgen by 6.6% in the 1st quarter. KFG Wealth Management LLC now owns 3,463 shares of the medical research company's stock valued at $1,079,000 after buying an additional 214 shares during the period. Butensky & Cohen Financial Security Inc. boosted its stake in Amgen by 0.3% in the first quarter. Butensky & Cohen Financial Security Inc. now owns 16,295 shares of the medical research company's stock worth $5,077,000 after buying an additional 47 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Amgen by 0.8% in the first quarter. Congress Asset Management Co. now owns 62,909 shares of the medical research company's stock worth $19,599,000 after buying an additional 473 shares during the period. Impact Capital Partners LLC boosted its holdings in Amgen by 4.3% in the first quarter. Impact Capital Partners LLC now owns 937 shares of the medical research company's stock valued at $292,000 after acquiring an additional 39 shares in the last quarter. Finally, Horizon Wealth Management LLC grew its position in shares of Amgen by 6.0% in the 1st quarter. Horizon Wealth Management LLC now owns 1,290 shares of the medical research company's stock worth $402,000 after buying an additional 73 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Shares of Amgen stock traded down $0.35 on Monday, hitting $289.98. The company's stock had a trading volume of 1,966,963 shares, compared to its average volume of 2,810,171. The company has a market capitalization of $155.92 billion, a P/E ratio of 38.41, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a fifty day moving average price of $281.26 and a 200-day moving average price of $285.36. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.96 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AMGN shares. UBS Group reaffirmed a "neutral" rating and set a $315.00 price target (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Bank of America increased their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Finally, Royal Bank of Canada cut their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $309.22.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president now directly owns 8,162 shares of the company's stock, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.76% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.